Northern Trust Corp increased its position in Protagonist Therapeutics Inc (NASDAQ:PTGX) by 24.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 98,825 shares of the company’s stock after purchasing an additional 19,159 shares during the period. Northern Trust Corp owned approximately 0.59% of Protagonist Therapeutics worth $1,118,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Rhumbline Advisers bought a new position in Protagonist Therapeutics during the 2nd quarter valued at $114,000. Teachers Advisors LLC increased its position in shares of Protagonist Therapeutics by 71.4% during the 2nd quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock valued at $183,000 after purchasing an additional 6,757 shares during the last quarter. Northern Capital Management LLC purchased a new stake in shares of Protagonist Therapeutics during the 2nd quarter valued at $188,000. TIAA CREF Investment Management LLC increased its position in shares of Protagonist Therapeutics by 19.5% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 23,372 shares of the company’s stock valued at $264,000 after purchasing an additional 3,812 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Protagonist Therapeutics by 5.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 27,626 shares of the company’s stock valued at $313,000 after purchasing an additional 1,478 shares during the last quarter. Institutional investors own 39.68% of the company’s stock.
Shares of Protagonist Therapeutics Inc (NASDAQ PTGX) opened at $18.99 on Friday. Protagonist Therapeutics Inc has a 12-month low of $8.00 and a 12-month high of $23.65.
Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Monday, November 6th. The company reported ($0.29) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.40. The company had revenue of $8.78 million during the quarter. sell-side analysts predict that Protagonist Therapeutics Inc will post -3.66 EPS for the current fiscal year.
In other Protagonist Therapeutics news, insider Richard S. Shames sold 2,017 shares of the business’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $19.00, for a total value of $38,323.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David Y. Liu sold 7,000 shares of the business’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $16.97, for a total value of $118,790.00. The disclosure for this sale can be found here. Insiders sold 9,892 shares of company stock worth $174,613 over the last three months. Corporate insiders own 15.50% of the company’s stock.
Several equities research analysts recently weighed in on PTGX shares. Zacks Investment Research raised Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Friday, August 18th. BidaskClub lowered Protagonist Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. BMO Capital Markets lifted their price target on Protagonist Therapeutics from $40.00 to $43.00 and gave the company an “outperform” rating in a research report on Tuesday, November 7th. Finally, ValuEngine upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $32.67.
WARNING: This story was published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.truebluetribune.com/2017/12/16/northern-trust-corp-purchases-19159-shares-of-protagonist-therapeutics-inc-ptgx.html.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.